Klein BC, Miceli R, Severt L, McAllister P, et al. Safety and tolerability results of atogepant for the preventive treatment of episodic migraine from a 40-week, open-label multicenter extension of the phase 3 ADVANCE trial. Cephalalgia 2023;43:3331024221128250.
PMID: 36620892